Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Technology ID
TAB-4135

3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases

E-Numbers
E-100-2018-0
Lead Inventors
Pasquet, Lise
Co-Inventors
Berzofsky, Jay
Howell, Amy
Terabe, Masaki
Camara, Kaddy
Applications
Therapeutics
Therapeutic Areas
Oncology
Immunology
Development Stages
Pre-clinical (in vivo)
Lead IC
NCI
ICs
NCI

Summary:

The NCI seeks research co-development partners and/or licensees for the sulfatide analog, C24:2

Description of Technology:

Lung metastases represent a major clinical challenge in advanced cancer, with poor survival rates and no effective therapies to prevent their development. Researchers at the National Cancer Institute (NCI) have developed C24:2, a first-in-class synthetic 3-O-sulfo-galactosylceramide analog. After lysosomal processing by dendritic cells, C24:2 switches immune specificity to activate type I NKT cells, triggering a potent IFN-γ–mediated Th1 response. This novel mechanism significantly reduces lung metastases in preclinical models and positions C24:2 as a promising candidate for next-generation cancer immunotherapy.

The structure and synthesis procedure of C24:2 are described in Patent Cooperation Treaty PCT/US2019/023890 which corresponds to E-100-2018 and for which Dr. Jay Berzofsky is the lead inventor. .

Potential Commercial Applications:

  • Therapeutic agent for lung metastases from different types of cancers
  • Immunomodulator for type I NKT cell
  • Combination therapy with checkpoint inhibitors or cancer vaccines

Competitive Advantages:

  • Addresses a high unmet need: No effective therapies currently exist for lung metastases.
  • First-in-class approach: Exploits a unique mechanism based on antigen processing and NKT cell subtype switching.
  • Broad cancer applicability: Effective against metastases from diverse tumor types.
  • Combination potential: May synergize with approved checkpoint inhibitors to boost patient outcomes
Licensing Contacts
Dattaroy, Diptadip
diptadip.dattaroy@nih.gov